Worth reading
51Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-637
Millions of yenWording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial Results PresentationFiscal year ending March 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales323 Millions of yen-66.4%
Operating profit-748 Millions of yen
Ordinary income-778 Millions of yen
Net income-780 Millions of yen
Full-year earnings forecast
Fiscal Period CoveredFiscal year ending March 2027
Net Sales
1,038 Millions of yen
Operating profit
-696 Millions of yen
Ordinary income
-625 Millions of yen
Net income for the current fiscal year
-628 Millions of yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Loss from lower sales-566 Millions of yen
- Increase in selling, general and administrative expenses-51 Millions of yen
- Manufacturing transfer costs-41 Millions of yen
New initiatives
- Transfer of the formulation process to a new manufacturing contractor
- Support for a Phase III investigator-initiated clinical trial for recurrent malignant glioma
- Support for the transition of newly diagnosed glioblastoma to Phase II
- Full-scale advancement of research and development for deep-seated cancers
- Development of next-generation PVA formulations for BNCT
- Establishment of a supply system for expansion into mainland China and overseas markets
Key KPIsA metric the company considers important as a management benchmark.
- Consumption-equivalent volume179 Box equivalent
Market Size / Share
In Japan, the patient population comprises approximately 4,000 patients with recurrent malignant glioma and approximately 2,200 patients with newly diagnosed glioblastoma. Among thoracic malignancies, there are approximately 20,000–30,000 annual cases of esophageal cancer, approximately 120,000 annual cases of lung cancer and approximately 90,000 annual cases of breast cancer.| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | 323 Millions of yen (YoY -66.4%) |
| Operating profit | -748 Millions of yen |
| Ordinary income | -778 Millions of yen |
| Net income | -780 Millions of yen |
| Full-year earnings forecast | Fiscal Period Covered Fiscal year ending March 2027 / Net Sales 1,038 Millions of yen / Operating profit -696 Millions of yen / Ordinary income -625 Millions of yen / Net income for the current fiscal year -628 Millions of yen |
| Breakdown of Factors Affecting the Change | Factors Loss from lower sales / Amount -566 Millions of yen, Factors Increase in selling, general and administrative expenses / Amount -51 Millions of yen, Factors Manufacturing transfer costs / Amount -41 Millions of yen |
| Key KPIs | Consumption-equivalent volume 179 Box equivalent |
| Market Size / Share | In Japan, the patient population comprises approximately 4,000 patients with recurrent malignant glioma and approximately 2,200 patients with newly diagnosed glioblastoma. Among thoracic malignancies, there are approximately 20,000–30,000 annual cases of esophageal cancer, approximately 120,000 annual cases of lung cancer and approximately 90,000 annual cases of breast cancer. |
| New initiatives | Transfer of the formulation process to a new manufacturing contractor, Support for a Phase III investigator-initiated clinical trial for recurrent malignant glioma, Support for the transition of newly diagnosed glioblastoma to Phase II, Full-scale advancement of research and development for deep-seated cancers, Development of next-generation PVA formulations for BNCT, Establishment of a supply system for expansion into mainland China and overseas markets |
Items this document does not state (20)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Overseas sales recorded in the previous fiscal year were not recorded in the current fiscal year, while personnel expenses and research and development expenses increased. For the fiscal year ending March 2027, revenue is expected to increase through the rebuilding of the manufacturing structure and sales to China, while losses are expected due to transfer costs for the new manufacturing contractor and continued investment in research and development and overseas expansion.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.